Home›Methenamine Sodium Phosphate Monobasic Monohydrate Phenyl Sa›Methenamine Sodium Phosphate Monobasic Monohydrate Phenyl Sa + Fluoxetine

Does Methenamine Sodium Phosphate Monobasic Monohydrate Phenyl Sa Interact with Fluoxetine?

Methenamine Sodium Phosphate Monobasic Monohydrate Phenyl Sa and Fluoxetine have a major drug interaction according to U.S. FDA drug labeling data. Methylene blue can cause serotonin syndrome; fluoxetine must be stopped at least 5 weeks before methylene blue treatment due to its longer half-life. The mechanism involves methylene blue inhibits monoamine oxidase a, preventing serotonin breakdown. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Methenamine Sodium Phosphate Monobasic Monohydrate Phenyl Sa and Fluoxetine occurs because methylene blue inhibits monoamine oxidase a, preventing serotonin breakdown. Clinically, this means methylene blue can cause serotonin syndrome; fluoxetine must be stopped at least 5 weeks before methylene blue treatment due to its longer half-life. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.

What To Tell Your Doctor or Pharmacist

If you are taking Methenamine Sodium Phosphate Monobasic Monohydrate Phenyl Sa and your doctor is considering prescribing Fluoxetine (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Methenamine Sodium Phosphate Monobasic Monohydrate Phenyl Sa(Mb Caps)+💊 Fluoxetine(Fluoxetine)

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
—
Drug B class
—
Source
NLP:methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate

What this means in plain English

Methylene blue can cause serotonin syndrome; fluoxetine must be stopped at least 5 weeks before methylene blue treatment due to its longer half-life.

What the FDA label says

"Methylene blue inhibits monoamine oxidase A, preventing serotonin breakdown"

📖 Source: NLP:methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate

Recent research & FDA safety updates

Live

Auto-aggregated from PubMed E-utilities and FDA safety data.

FDA
Share this result:XFacebookWhatsAppReddit
Add more drugs
Check Methenamine Sodium Phosphate Monobasic Monohydrate Phenyl Sa and Fluoxetine against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.